The Climb to Success
Ekso Bionics Holdings (NasdaqCM:EKSO) has witnessed a remarkable surge in its average one-year price target, now standing at a solid 10.20 per share. This surge of 11.11% from the previous estimate of 9.18 dated January 16, 2024, has grabbed the attention of investors worldwide.
Analysts’ Insight
The price target is an aggregation of several targets provided by analysts. The most recent targets span from a low of 10.10 to a high of 10.50 per share. When we compare this with the latest reported closing price of 1.92 per share, the average price target represents a whopping increase of 431.25%.
Have Fund Sentiments Altered?
Over the last quarter, there has been a decrease of 5 owners or 10.64% in the 42 funds or institutions reporting positions in Ekso Bionics Holdings. The average portfolio weight dedicated to EKSO for all funds has surged by 607.75%, hitting 0.00%. During the last three months, total shares owned by institutions have seen a rise of 2.47%, now resting at 1,154K shares.
The put/call ratio of EKSO is currently sitting at 0.32, indicating a bullish outlook in the near future for the company.
Actions of Other Shareholders
Key shareholders like Vanguard Total Stock Market Index Fund Investor Shares (VTSMX) continue to show faith in Ekso Bionics Holdings, holding 243K shares representing 1.37% ownership of the company, with no changes in the last quarter. Similarly, Vanguard Extended Market Index Fund Investor Shares (VEXMX) and Essex Investment Management Co have also maintained their positions in the company, reflecting a mix of stability and change.
Essex Investment Management Co, however, reported a notable decrease in their ownership by 39.87% with 158K shares currently. Through strategic moves, the firm hiked its portfolio allocation in EKSO by an impressive 194.14% over the past quarter.
Other prominent players like Kent Lake Capital and Geode Capital Management have also kept a foothold in Ekso Bionics Holdings, showcasing a diverse landscape of shareholders.
A Glimpse into the Company’s Roots
Ekso Bionics® has been at the forefront of developing exoskeleton solutions since its inception in 2005. The company’s mission to amplify human potential by bolstering strength, endurance, and mobility across medical and industrial sectors has garnered widespread acclaim. With innovative wearable robots that cater to a spectrum of needs, from aiding paralysis patients to enhancing human capabilities in work environments globally, Ekso Bionics stands as a beacon of innovation in the San Francisco Bay Area.
Fintel, a premier investing research platform, serves as a comprehensive resource for individual investors, traders, financial advisors, and small hedge funds.
Providing data that covers a wide array of factors such as fundamentals, analyst reports, ownership data, fund sentiment, options sentiment, and insider trading activities, Fintel strives to empower investors with actionable insights. Additionally, Fintel’s exclusive stock picks, driven by advanced, backtested quantitative models, aim to boost profitability for investors.
As the market dynamics evolve, Ekso Bionics Holdings is positioned to leverage its innovative solutions and industry expertise to propel further growth and success.
This story was originally featured on Fintel.
The expressions and opinions articulated here belong solely to the author and may not necessarily align with the views of Nasdaq, Inc.
